Core Viewpoint - The leading medical aesthetics company, Aimeike, has decided to reclaim the exclusive agency rights for the product "Aisufei" in China from *ST Suwu, which previously held the rights through its subsidiary, Datou Medical. This decision has sparked a strong reaction from *ST Suwu, which accuses Aimeike of violating antitrust laws and acting unethically [2][4]. Group 1: Company Actions and Reactions - Aimeike's subsidiary REGEN has terminated the exclusive agency agreement for Aisufei, a regenerative aesthetic injection product, citing violations by Datou Medical [2][4]. - *ST Suwu has publicly condemned Aimeike's actions, claiming they are unethical and calling for government intervention [2][4]. - Aimeike's global market head stated that the termination is a legitimate action to protect their rights and that they refuse to partner with companies that engage in fraudulent activities [5][6]. Group 2: Financial Implications - Aisufei is expected to generate significant revenue, with projected sales of 326 million yuan and a gross profit of 269 million yuan in 2024 [2]. - Following the termination of the agency rights, *ST Suwu's revenue and profits from its medical aesthetics segment are likely to decline significantly in the second half of the year [7]. - Aimeike reported a revenue of 3.026 billion yuan in 2024, with a year-on-year growth of 5.45%, while its net profit saw a slight increase of 2.2% [8]. Group 3: Legal and Regulatory Context - The exclusive agency agreement was originally set to last until August 28, 2032, but Aimeike claims that *ST Suwu's violations justify the termination [3][4]. - The China Securities Regulatory Commission has penalized *ST Suwu for various violations, including inflated revenue reporting, which has raised concerns about its operational integrity [4][5]. - Aimeike has indicated that if disputes arise, they will rely on legal frameworks to resolve them, emphasizing the importance of compliance and ethical conduct in business partnerships [5].

Core Viewpoint - The exclusive distribution rights of *ST Suwu's subsidiary, Datou Medical, are set to be revoked by Aimeike, which could significantly impact *ST Suwu's medical aesthetics business revenue and profits in the second half of 2025 [5][6][15]. Group 1: Company Actions and Implications - Aimeike's subsidiary, REGEN Biotech, Inc., sent a termination notice to Datou Medical on July 18, 2023, to revoke its exclusive distribution rights for the AestheFill product in mainland China [5][9]. - If the termination is finalized, Datou Medical will be unable to sell AestheFill products, leading to a substantial decrease in revenue and profit for *ST Suwu's medical aesthetics segment [6][15]. - In 2024, AestheFill contributed 326 million yuan to *ST Suwu's total revenue, accounting for 20.42%, and in Q1 2025, it generated 113 million yuan, representing 35.55% of the company's revenue [6][16][17]. Group 2: Legal and Regulatory Context - *ST Suwu has denied any breach of contract and plans to take legal action to protect its rights [6][20]. - The termination notice cites that Datou Medical allegedly transferred its exclusive distribution business to its parent company, Jiangsu Wuzhong Meisheng Biotechnology Co., Ltd., which violates the agreement [21][22]. - Recent regulatory issues have plagued *ST Suwu, including administrative penalties for violations of securities laws, which could lead to significant consequences, including potential delisting [24][26].

Core Viewpoint - The article discusses the termination of the exclusive distribution rights of AestheFill products held by Dato Medical, a subsidiary of *ST Suwu, by REGEN Biotech, a subsidiary of Aimeike, due to alleged breaches of contract. This move is expected to significantly impact *ST Suwu's medical aesthetics business revenue and profits in the second half of 2025 [6][10][18]. Summary by Sections Company Actions - Aimeike's subsidiary REGEN sent a termination notice to Dato Medical on July 18, 2025, to revoke its exclusive distribution rights for AestheFill products in mainland China [6][12]. - The termination is based on Dato Medical's alleged transfer of its exclusive distribution business to its parent company, Jiangsu Wuzhong Meisheng Biotechnology Co., Ltd., which violates the agreement [21][22]. Financial Impact - In 2024, AestheFill contributed revenue of 326 million yuan, accounting for 20.42% of *ST Suwu's total revenue, with a gross profit of 269 million yuan, representing 34.80% of the company's gross profit [10][18]. - In the first quarter of 2025, AestheFill generated revenue of 113 million yuan, making up 35.55% of *ST Suwu's revenue, with a gross profit of approximately 92.44 million yuan, which is 45.77% of the company's gross profit [10][18]. Legal and Regulatory Context - *ST Suwu has denied any breach of contract and plans to take legal action to protect its rights [10][19]. - The company has faced regulatory scrutiny, including a notice from the China Securities Regulatory Commission regarding violations of securities laws, which could lead to severe penalties and potential delisting risks [24][25].

Core Viewpoint - A dispute has arisen between two A-share companies regarding the exclusive distribution rights of the AestheFill product, with *ST Suwu asserting its rights against Regen Biotech, a subsidiary of Aimeike [2][3] Group 1: Dispute Details - *ST Suwu claims that Regen Biotech intends to terminate the exclusive distribution agreement for AestheFill in mainland China, citing alleged violations of the agreement by *ST Suwu and its executives [2][3] - Regen Biotech has sent a termination notice to *ST Suwu, asserting that the latter has transferred the distribution rights to its controlling shareholder, Wu Zhong Meixue, which they claim violates the agreement [2][3] - *ST Suwu refutes these claims, stating that there has been no transfer of rights and that the exclusive distribution agreement remains legally binding until 2032 [3] Group 2: Product and Market Impact - AestheFill is a regenerative injection product developed by Regen Biotech, primarily composed of PDLLA microspheres and sodium carboxymethyl cellulose, aimed at skin rejuvenation [4] - The product was first approved for sale in South Korea in 2014, and *ST Suwu acquired a 51% stake in the distributor, Dato Medical, in 2021 for 166 million yuan [4][5] - AestheFill generated significant revenue for *ST Suwu, contributing 3.26 billion yuan to the company's total revenue in 2024, accounting for 20.42% of total revenue and 34.80% of gross profit [6] Group 3: Corporate Developments - Aimeike recently acquired 85% of Regen Biotech for approximately 1.386 billion yuan, gaining control over the company and integrating it into its financial statements [5][6] - The sales performance of AestheFill is critical for *ST Suwu, especially as the company faces a potential delisting due to regulatory issues related to financial misreporting [6]

Core Viewpoint - Jiangsu Wuzhong's subsidiary, Datou Medical, has received a termination letter from Regen Biotech, which demands the cancellation of Datou Medical's exclusive distribution rights for the AestheFill product in mainland China, raising concerns about the company's future in the medical aesthetics sector amid ongoing financial scandals [1][2]. Group 1: Company Response and Legal Actions - Jiangsu Wuzhong has initiated a response plan upon receiving the termination letter and is in communication with Regen, indicating that legal action may be taken if necessary to protect its rights [2]. - Regen's reasons for termination include allegations that Datou Medical transferred exclusive distribution rights to its parent company, and concerns over Jiangsu Wuzhong's legal violations affecting the product's reputation [2]. Group 2: Market Impact and Financial Performance - The change in the registration agent for AestheFill from Datou Medical to Lizhen (Beijing) Biotechnology Co., owned by Regen, introduces uncertainty regarding the previously secure exclusive distribution agreement [4]. - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion yuan, a decline of 28.64% year-on-year, with the medical aesthetics segment generating 330 million yuan, a significant increase of over 40 times [4]. - If the exclusive distribution agreement is ultimately terminated, Datou Medical would lose its rights to sell AestheFill, leading to a substantial decrease in revenue and profit for the medical aesthetics segment in the latter half of the year [5].

Core Viewpoint - The dispute over the agency rights for the "Youthful Needle" AestheFill has escalated, with Jiangsu Wuzhong's subsidiary receiving a termination notice from REGEN, which will revoke its exclusive distribution rights in mainland China [1][2]. Group 1: Company Impact - Jiangsu Wuzhong's subsidiary, Datou Medical, received a termination letter from REGEN, which will withdraw all related authorizations for AestheFill's exclusive distribution in mainland China [1]. - AestheFill generated revenue of 326 million yuan within six months of its launch in April 2024, contributing to Jiangsu Wuzhong's turnaround with a net profit of 70 million yuan last year [1]. - The revenue for AestheFill reached 113 million yuan in the first quarter of this year, highlighting its significance for Jiangsu Wuzhong, which is already facing challenges due to previous financial misreporting [1]. Group 2: Market Dynamics - The announcement from Jiangsu Wuzhong on July 17 claimed that the medical beauty business was operating normally and that the change in registration agent would not affect the exclusive agency rights, only to be contradicted by the termination notice from REGEN the following day [2]. - The change of the registration agent from Datou Medical to Lizhen Biotechnology, a company controlled by REGEN, suggests prior negotiations that Jiangsu Wuzhong did not disclose, raising questions about their information disclosure practices [3]. - The market for "Youthful Needles" is becoming increasingly competitive, with multiple approvals for similar products from various companies, including four new products approved in less than seven months this year [7][8].

Core Viewpoint - The company *ST Suwu (600200.SH)* faces potential loss of exclusive distribution rights for AestheFill products in mainland China due to a termination notice from Regen Biotech, which could significantly impact its revenue and profit from the medical aesthetics segment [1][2][3] Group 1: Agreement and Sales Performance - DaTou Medical obtained exclusive distribution rights for AestheFill products in mainland China through an agreement effective until August 28, 2032 [1] - In 2024, AestheFill sales revenue reached 326.41 million yuan, accounting for 20.42% of the company's total revenue, with a gross profit of 268.84 million yuan, representing 34.80% of total gross profit [3] - In Q1 2025, AestheFill sales revenue was 112.77 million yuan, making up 35.55% of the company's total revenue, with a gross profit of 92.44 million yuan, which is 45.77% of total gross profit [3] Group 2: Termination Notice and Company Response - Regen issued a termination notice citing violations of the agreement by DaTou Medical, including the alleged transfer of exclusive distribution rights to its controlling shareholder [2] - The termination would revoke DaTou Medical's status as the exclusive distributor for AestheFill products, halting any business activities under this capacity [2] - The company has initiated a response plan and is in communication with Regen, considering legal action to protect its rights, asserting that it has not transferred the exclusive rights [3]

重要风险提示： 江苏吴中医药发展股份有限公司（以下简称"公司"）股票连续三个交 易日内收盘价格跌幅偏离值累计超过 12%，属于股票交易异常波动的情形。 2025 年 7 月 13 日，公司收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《行政处罚事先告知书》（处罚字〔2025〕58 号），具体 内容详见公司于 2025 年 7 月 14 日披露的《关于收到中国证券监督管理委员会< 行政处罚事先告知书>的公告》（公告编号：临 2025-064）。公司股票已于 2025 年 7 月 14 日起被叠加实施退市风险警示，如根据中国证监会正式的处罚决定书 结论，公司触及重大违法强制退市情形，公司股票将被终止上市。敬请广大投资 者关注后续公告并注意投资风险。 个证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-073 江苏吴中医药发展股份有限公司 股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司 2024 年度财务报告被年审机构出具无法表示意见，触及《上海证券 交易所股票上市规则》 ...

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-072 江苏吴中医药发展股份有限公司 关于控股孙公司收到《解约函》的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 一、基本概况 江苏吴中医药发展股份有限公司（以下简称"公司"）控股孙公司达透医疗 器械（上海）有限公司（以下简称"达透医疗"）于 2022 年 8 月与 Dace International Medical Co., Ltd 以及 Regen Biotech Inc.（"Regen"，其于 2025 年 7 月成为爱美客技术发展股份有限公司(300896.SZ)的控股子公司）三方 共同签署了《关于 AestheFill 独家销售代理权转让协议》（同此前签署的一系 列协议以及修订协议，合称为"《独家代理权协议》"），达透医疗取得 AestheFill 相关产品在中国大陆的独家经销权。 根据《独家代理权协议》的明确约定，达透医疗拥有 AestheFill 产品在中 国境内的独家代理权，有效期至 2032 年 8 月 28 日；且 Regen 承诺 ...

New Stock Issuance - The new stock issued by Hanguo Group is priced at 15.43 RMB per share[1] - The subscription period for the tender offer of ST Kelly is from July 17, 2025, to August 15, 2025[1] Abnormal Fluctuations - Several stocks, including ST Zitian and Guangshengtang, have reported severe abnormal fluctuations[2] - The announcement links for stocks experiencing abnormal fluctuations are provided for investor reference[2] Market Updates - A total of 30 stocks have been listed for trading updates, with various announcements made between July 15 and July 21, 2025[1] - The report includes links to detailed announcements for each stock, ensuring transparency and accessibility for investors[1]